Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.40 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3779088 | 0.88 | DDB1 (0.39) | DDB1CRBNNR1H2NR1H3CYP2C19 | |
| SCHEMBL3787665 | 0.78 | KCNA5 (0.42) | CYP2C19SMN1; SMN2 | |
| SCHEMBL3781275 | 0.77 | CYP17A1 (0.49) | — | |
| SCHEMBL1044762 | 0.77 | SMN1; SMN2 (0.42) | CYP2C19SMN1; SMN2 | |
| SCHEMBL3782495 | 0.76 | SMN1; SMN2 (0.52) | CYP2C19SMN1; SMN2 | |
| SCHEMBL1039613 | 0.75 | CPB2 (0.40) | CPB2 | |
| SCHEMBL27567104 | 0.75 | LMNA (0.51) | — | |
| SCHEMBL1043158 | 0.74 | SMN1; SMN2 (0.44) | NR1H2NR1H3CYP2C19SMN1; SMN2 | |
| SCHEMBL3776399 | 0.73 | SMN1; SMN2 (0.54) | CYP2C19SMN1; SMN2 | |
| SCHEMBL1665018 | 0.72 | TSHR (0.39) | NR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8309341-B2 | 2-mercaptocyclopentanecarboxylic acid compounds, a process for their preparation and pharmaceutical compositions containing them | Les Laboratories Server (FR) | 2012-11-13 | — | — | US | disclosed |
| US-20100330064-A1 | 2-mercaptocyclopentanecarboxylic acid compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100330064-A1 | 2-mercaptocyclopentanecarboxylic acid compounds, a process for their preparation and pharmaceutical compositions containing them | CYP2B6, CYP2A6, MC5R | CPB2 1603/4885DDB1 4038/4885CRBN 764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.